PRESS RELEASE published on 10/21/2025 at 10:42, 10 months 22 days ago Franchissement de seuils Déclaration de franchissement de seuils par Vester Finance pour ADOCIA avec 889 555 actions, 4,86% du capital et 4,36% des droits de vote Déclaration Actions Franchissement De Seuils ADOCIA Vester Finance
BRIEF published on 10/15/2025 at 08:50, 10 months 28 days ago Résultats positifs pour l'insuline BioChaperone® Lispro en Phase 3 Essai Clinique Diabète De Type 1 ADOCIA BioChaperone® Tonghua Dongbao
BRIEF published on 10/15/2025 at 08:50, 10 months 28 days ago Positive results for BioChaperone® Lispro insulin in Phase 3 Clinical Trial Type 1 Diabetes ADOCIA BioChaperone® Tonghua Dongbao
PRESS RELEASE published on 10/15/2025 at 08:45, 10 months 28 days ago Inside Information / Other news releases ADOCIA and Tonghua Dongbao announce positive Phase 3 results for Ultra-Rapid Insulin BioChaperone Lispro in Type 1 Diabetes treatment, showing non-inferior HbA1c reduction and improved blood glucose control post-meal Type 1 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
PRESS RELEASE published on 10/15/2025 at 08:45, 10 months 28 days ago Informations privilégiées / Autres communiqués Adocia et Tonghua Dongbao annoncent des résultats positifs d'essai clinique de Phase 3 sur l'insuline BioChaperone® Lispro THDB0206 injection pour le Diabète de Type 1 en Chine Diabète De Type 1 ADOCIA Tonghua Dongbao Insuline BioChaperone Lispro
BRIEF published on 07/25/2025 at 08:50, 1 year 1 month ago Adocia et Tonghua Dongbao annoncent le succès de la phase 3 de leur projet d'insuline ultra-rapide Essai Clinique Traitement Du Diabète ADOCIA Résultats De La Phase 3 BioChaperone® Lispro
BRIEF published on 07/25/2025 at 08:50, 1 year 1 month ago Adocia and Tonghua Dongbao Report Phase 3 Success for Ultra-Rapid Insulin Diabetes Treatment Clinical Trial Phase 3 Results ADOCIA BioChaperone® Lispro
PRESS RELEASE published on 07/25/2025 at 08:45, 1 year 1 month ago Informations privilégiées / Autres communiqués ADOCIA et Tonghua Dongbao annoncent des résultats positifs de l'essai clinique de Phase 3 sur l'insuline ultra-rapide BioChaperone® Lispro pour le diabète de Type 2 en Chine Essai Clinique Diabète De Type 2 ADOCIA Tonghua Dongbao Insuline Ultra-rapide
PRESS RELEASE published on 07/25/2025 at 08:45, 1 year 1 month ago Inside Information / Other news releases Adocia and Tonghua Dongbao announce positive Phase 3 results of Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in Type 2 Diabetes. Significant HbA1c reduction and improved post-meal blood glucose levels compared to Humalog® Type 2 Diabetes Phase 3 Results ADOCIA Tonghua Dongbao Ultra-Rapid Insulin
BRIEF published on 04/04/2025 at 11:21, 1 year 5 months ago Vester Finance reduces its stake in ADOCIA Voting Rights Actions Threshold Crossing ADOCIA Vester Finance
Published on 09/12/2026 at 02:35, 11 hours 18 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 53 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 48 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 28 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 53 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 23 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 38 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 43 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 8 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 38 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
